Stock Events

Dyne Therapeutics 

$33.03
16
-$0.62-1.84% Friday 20:00

Statistics

Day High
34.11
Day Low
31.57
52W High
47.45
52W Low
6.4
Volume
1,406,128
Avg. Volume
1,273,806
Mkt Cap
4.63B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

31
OCT
Earnings
 

Earnings

31OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.09
-0.96
-0.83
-0.7
Expected EPS
-0.70352
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DYN. It's not an investment recommendation.
Alphabet
72554
GOOGL
Apple
63389
AAPL
Microsoft
59081
MSFT
Amazon
54705
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap12.95B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, similar to Dyne's focus on muscle diseases.
Ionis Pharmaceuticals
IONS
Mkt Cap6.97B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing in the same space as Dyne with a focus on genetic and rare diseases.
PTC Therapeutics
PTCT
Mkt Cap2.72B
PTC Therapeutics operates in the field of genetic disorders, including Duchenne muscular dystrophy, which overlaps with Dyne's therapeutic areas.
Solid Biosciences
SLDB
Mkt Cap344.66M
Solid Biosciences is focused on treatments for Duchenne muscular dystrophy, directly competing with Dyne's muscle disease programs.
Wave Life Sciences
WVE
Mkt Cap716M
Wave Life Sciences is involved in designing, discovering, and developing RNA therapeutics for genetically defined diseases, competing in the same niche as Dyne.
Ultragenyx Pharmaceutical
RARE
Mkt Cap5.23B
Ultragenyx Pharmaceutical focuses on rare and ultra-rare diseases, including genetic disorders, which is a direct competition to Dyne's focus areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap17.36B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including genetic disorders.
Alnylam Pharmaceuticals
ALNY
Mkt Cap33.72B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, targeting genetic diseases, which puts it in competition with Dyne.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine works on gene editing technologies, including CRISPR, to treat genetic diseases, offering an alternative approach to Dyne's RNA-focused therapies.

Analyst Ratings

50.89$Average Price Target
The highest estimate is $66.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Commercial Services
Miscellaneous Commercial Services
Health Technology
Biotechnology
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Show more...
CEO
Joshua T. Brumm
Employees
152
Country
US
ISIN
US26818M1080

Listings

XNAS
US
DYN